Payment overview · 2025
General Payments
$2,937.04
118 reported records · 18 companies
Healthcare provider profile · identity verified
Duc Nguyen, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · SIMI VALLEY, CA · NPI 1306945365
Verified facts
What the public records show
CMS Open Payments records show Duc Nguyen, MD received $2,937.04 in general payments during 2025 across 118 reported records.
AstraZeneca Pharmaceuticals LP accounted for 17.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Linzess, Mounjaro, Ozempic, Paxlovid, Prolia, Uptravi.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
Actelion Pharmaceuticals US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UPTRAVI as an associated drug or biological on 21562 records involving 9341 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Uptravi by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 500 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $515.05 | 17.5% | 18 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $434.16 | 14.8% | 23 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $419.38 | 14.3% | 21 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $407.92 | 13.9% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $270.69 | 9.2% | 9 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $179.79 | 6.1% | 11 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $163.16 | 5.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $98.09 | 3.3% | 5 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $90.37 | 3.1% | 3 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $88.64 | 3.0% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $52.21 | 1.8% | 2 | 2025 |
| Pulmonx Corporation | Unresolved — no canonical attribution shown | $49.16 | 1.7% | 2 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $45.13 | 1.5% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $30.02 | 1.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.15 | 0.9% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $23.50 | 0.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $22.79 | 0.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $21.83 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,903.04 | 117 |
| Education | $34.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc., AstraZeneca Pharmaceuticals LP | $634.02 | 26 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $419.38 | 21 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $395.13 | 9 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $340.86 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $278.24 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $198.60 | 4 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $179.79 | 11 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $179.01 | 6 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $175.55 | 3 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $163.16 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $146.82 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $98.28 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $79.31 | 4 | 2025 |
Source payment records
|
|||||
| OPSYNVI Normalized: opsynvi |
Drug | Actelion Pharmaceuticals US, Inc. | $67.06 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $63.31 | 3 | 2025 |
Source payment records
|
|||||
| CHARTIS CATHETER Normalized: chartis catheter |
Device | Pulmonx Corporation | $49.16 | 2 | 2025 |
Source payment records
|
|||||
| PULMONX CHARTIS TABLET CONSOLE Normalized: pulmonx chartis tablet console |
Device | Pulmonx Corporation | $49.16 | 2 | 2025 |
Source payment records
|
|||||
| ZEPHYR DELIVERY CATHETER Normalized: zephyr delivery catheter |
Device | Pulmonx Corporation | $49.16 | 2 | 2025 |
Source payment records
|
|||||
| ZEPHYR ENDOBRONCHIAL VALVE Normalized: zephyr endobronchial valve |
Device | Pulmonx Corporation | $49.16 | 2 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $45.13 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $30.02 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $29.48 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $29.48 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $28.57 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $25.59 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $25.15 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $23.64 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $23.64 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $23.64 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $23.50 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $23.50 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $22.79 | 1 | 2025 |
Source payment records
|
|||||
| WINREVAIR Normalized: winrevair |
Biological | Merck Sharp & Dohme LLC | $21.83 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.82 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $18.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 75 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 26 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 96 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 12 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 35 | exact normalized | Medicare Part D |
| UPTRAVI uptravi |
2025 | Uptravi | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
26 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Actelion Pharmaceuticals US, Inc. Exact reporting entity; no affiliate inference |
2025 | UPTRAVI open payments reported associated product |
CMS Open Payments — General Payments 21562 supporting records · 9341 recipient NPIs · example record 1174163984 |
Uptravi · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
35 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
500 | 169 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
75 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
96 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
134 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 500 | 169 |
| Atorvastatin Calcium | Atorvastatin Calcium | 430 | 124 |
| Amlodipine Besylate | Amlodipine Besylate | 398 | 112 |
| Prednisone | Prednisone | 302 | 209 |
| Levothyroxine Sodium | Levothyroxine Sodium | 271 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 257 | 95 |
| Valsartan | Valsartan | 230 | 70 |
| Metformin Hcl | Metformin Hcl | 225 | 59 |
| Fluticasone Propionate | Fluticasone Propionate | 211 | 86 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 202 | 106 |
| Tamsulosin Hcl | Tamsulosin Hcl | 195 | 49 |
| Azithromycin | Azithromycin | 169 | 129 |
| Zolpidem Tartrate | Zolpidem Tartrate | 169 | 44 |
| Furosemide | Furosemide | 158 | 56 |
| Lisinopril | Lisinopril | 146 | 39 |
| Eliquis | Apixaban | 134 | 30 |
| Potassium Chloride | Potassium Chloride | 133 | 41 |
| Gabapentin | Gabapentin | 132 | 43 |
| Losartan Potassium | Losartan Potassium | 127 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 127 | 34 |
| Trazodone Hcl | Trazodone Hcl | 126 | 34 |
| Omeprazole | Omeprazole | 123 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 119 | 39 |
| Celecoxib | Celecoxib | 114 | 48 |
| Azelastine Hcl | Azelastine Hcl | 111 | 53 |
| Simvastatin | Simvastatin | 108 | 30 |
| Carvedilol | Carvedilol | 105 | 32 |
| Montelukast Sodium | Montelukast Sodium | 99 | 39 |
| Mounjaro | Tirzepatide | 96 | 24 |
| Sertraline Hcl | Sertraline Hcl | 91 | 24 |
| Finasteride | Finasteride | 87 | 28 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 80 | 32 |
| Breo Ellipta | Fluticasone/Vilanterol | 75 | 27 |
| Jardiance | Empagliflozin | 75 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 74 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 74 | 34 |
| Donepezil Hcl | Donepezil Hcl | 71 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 70 | 11 |
| Lorazepam | Lorazepam | 70 | 15 |
| Glimepiride | Glimepiride | 67 | 16 |
| Theophylline Er | Theophylline Anhydrous | 66 | 34 |
| Famotidine | Famotidine | 65 | 23 |
| Alendronate Sodium | Alendronate Sodium | 64 | 12 |
| Allopurinol | Allopurinol | 63 | 19 |
| Fenofibrate | Fenofibrate | 63 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 63 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 62 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 20 |
| Levofloxacin | Levofloxacin | 59 | 53 |
| Alprazolam | Alprazolam | 58 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 55 | 35 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 54 | 45 |
| Cephalexin | Cephalexin | 53 | 37 |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 51 | 17 |
| Clonazepam | Clonazepam | 50 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 46 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 12 |
| Clarithromycin | Clarithromycin | 44 | 38 |
| Clonidine Hcl | Clonidine Hcl | 43 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | 15 |
| Ipratropium Bromide | Ipratropium Bromide | 41 | 24 |
| Lidocaine | Lidocaine | 41 | 11 |
| Pregabalin | Pregabalin | 40 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 28 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 37 | 12 |
| Memantine Hcl | Memantine Hcl | 37 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 36 | 15 |
| Estradiol | Estradiol | 35 | suppressed |
| Prolia | Denosumab | 35 | 22 |
| Terazosin Hcl | Terazosin Hcl | 35 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 33 | suppressed |
| Xarelto | Rivaroxaban | 33 | 11 |
| Digoxin | Digoxin | 31 | suppressed |
| Glipizide | Glipizide | 31 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 31 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 30 | 17 |
| Metolazone | Metolazone | 30 | 12 |
| Atenolol | Atenolol | 29 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 29 | suppressed |
| Amoxicillin | Amoxicillin | 28 | 12 |
| Clobetasol Propionate | Clobetasol Propionate | 28 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Chlorthalidone | Chlorthalidone | 26 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Linzess | Linaclotide | 26 | 11 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 26 | 13 |
| Bumetanide | Bumetanide | 25 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 23 | suppressed |
| Methotrexate | Methotrexate Sodium | 23 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 16 |
| Dexlansoprazole Dr | Dexlansoprazole | 22 | 11 |
| Diazepam | Diazepam | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Meloxicam | Meloxicam | 21 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Tradjenta | Linagliptin | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Carisoprodol | Carisoprodol | 20 | suppressed |
| Clotrimazole | Clotrimazole | 20 | 11 |
| Colchicine | Colchicine | 20 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | suppressed |
| Ozempic | Semaglutide | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 18 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 17 | 16 |
| Dextroamphetamine Sulfate Er | Dextroamphetamine Sulfate | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 12 |
| Breyna | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Uptravi | Selexipag | 12 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Cyclosporine | Cyclosporine | 11 | suppressed |
| Dupixent Syringe | Dupilumab | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Ofev | Nintedanib Esylate | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,937.04 · 118 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, Arikayce, BREZTRI, CHARTIS CATHETER, COMIRNATY, DUPIXENT, EVENITY, FASENRA, INSPIRE, JARDIANCE, Korlym, LEQVIO, LINZESS, MOUNJARO, NUCALA, OPSUMIT, OPSYNVI, Ozempic, PAXLOVID, PREVNAR 20, PROLIA, PULMONX CHARTIS TABLET CONSOLE, QULIPTA, Rybelsus, TEZSPIRE, UBRELVY, UPTRAVI, VOQUEZNA, VRAYLAR, WINREVAIR, YUPELRI, ZEPBOUND, ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error